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Core evidence proof of concept summary for aliskiren in hypertension

  **Outcome measure**                                                                                                     **Emerging evidence**
  ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Disease-oriented evidence**                                                                                           
  Blood pressure lowering in monotherapy                                                                                  Aliskiren as monotherapy is effective for treatment of hypertension and may be as effective as an ARB
  Blood pressure lowering in combination therapy                                                                          Pilot trials demonstrate efficacy in combination with valsartan in normotensive individuals
  Blood pressure lowering in other categories of patient (i.e. severe hypertension, elderly, different races, children)   No evidence
  Renal-protective effect                                                                                                 No evidence
  **Patient-oriented evidence**                                                                                           
  Tolerability                                                                                                            Aliskiren is highly tolerable and is probably as well tolerated as an ARB. Useful in patients who cannot tolerate other drugs, especially ACE inhibitors
  Adherence                                                                                                               Aliskiren's high tolerability and adherence in phase II suggest patients will adhere to aliskiren therapy to the same extent as with an ARB
  Decrease in major cardiovascular events                                                                                 No evidence
  Decrease in mortality                                                                                                   No evidence
  **Economic evidence**                                                                                                   
  Cost effectiveness                                                                                                      No evidence

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.

Scope, aims, and objectives
===========================

Aliskiren (Novartis) is the first in a new class of antihypertensive drugs called renin inhibitors that inhibit the conversion of angiotensinogen to angiotensin I by renin. Renin inhibition blocks production of angiotensin II, a key mediator in the regulation of body fluid volume and blood pressure.

The objective of this article is to review the available evidence, limited to phase II trials and pilot trials, for the use of aliskiren in patients with hypertension, evaluating its effects on available measured outcomes including blood pressure, adherence, and tolerability. In addition, this article will provide an overview of the disease, current treatment options, and pharmacoeconomic considerations regarding antihypertensive drugs. Finally, given the available outcomes evidence a discussion of aliskiren's preliminary place in therapy will be presented.

Methods
=======

Literature searches were conducted on January 31, March 2, and May 8, 2005 in the databases listed below. The search terms were "aliskiren" and "SPP100" with no search tags unless otherwise stated. Results were limited to English-language articles only. No date limitations were imposed unless otherwise noted.

-   PubMed, [www.ncbi.nlm.nih.gov/entrez](www.ncbi.nlm.nih.gov/entrez), 1966 to date

-   EMBASE, [www.datastarweb.com](www.datastarweb.com), 1974 to date

-   Database of Abstracts of Reviews of Effectiveness (DARE), NHS Economic Evaluations Database (NHSEED), Health Technology Assessment (HTA), [www.york.ac.uk/inst/crd/darehp.htm](www.york.ac.uk/inst/crd/darehp.htm)

-   NHS HTA, [www.ncchta.org](www.ncchta.org)

-   National Guidelines Clearinghouse, [www.guideline.gov](www.guideline.gov)

-   National Institute for Health and Clinical Excellence (NICE), [www.nice.org.uk](www.nice.org.uk)

-   Cochrane Database of Systematic Reviews, [www.cochrane.org](www.cochrane.org)

-   Clinical Evidence, [www.clinicalevidence.com](www.clinicalevidence.com)

-   American Society for Hypertension (ASH) abstract database, [www.abstracts2view.com/ash/](www.abstracts2view.com/ash/)

After removal of duplicates a total of 28 citations were identified from PubMed, EMBASE, and ASH; no additional citations were identified from the other databases. Records were manually reviewed and 22 citations were excluded: animal studies (n=1), nonsystematic reviews (n=12), and citations that mentioned aliskiren but did not investigate its clinical use (n=9). No systematic reviews of aliskiren have been published.

Inclusion criteria for the outcomes analysis of aliskiren used an accepted scale of hierarchy of evidence (see Editorial Information on inside back cover). All randomized, controlled clinical trials of aliskiren (evidence level 2) were included ([Table 1](#t1-ce-1-013){ref-type="table"}).

Introduction
============

Aliskiren is an oral antihypertensive drug that inhibits the conversion of angiotensinogen to angiotensin I by renin, the first step of the renin-angiotensin system (RAS) and a rate-limiting step in the production of angiotensin II ([Fig. 1](#f1-ce-1-013){ref-type="fig"}). Angiotensin I is then metabolized by angiotensin-converting enzyme (ACE) and other enzymes to yield angiotensin II, a key mediator in the regulation of body fluid volume and blood pressure. Angiotensin II controls body fluid volume both directly by stimulating sodium reabsorption in the proximal tubule of the kidney, and indirectly through stimulation of aldosterone release. Angiotensin II is also a potent vasoconstrictor that acts on arterioles to increase systemic blood pressure. Inhibitors of other steps in the RAS pathway ([Fig. 1](#f1-ce-1-013){ref-type="fig"}), including ACE inhibitors that block the conversion of angiotensin I to angiotensin II and angiotensin receptor blockers (ARBs) that inhibit binding of angiotensin II to type I angiotensin II receptors (AT-1), are currently in clinical use as antihypertensive agents.

Research suggests that hypertension is related to vascular damage, oxidative stress, and inflammation. Angiotensin II, one of the key mediators in hypertensive disease, has been shown to act as a proinflammatory mediator that increases vascular permeability, promotes recruitment of inflammatory cells, and activates the infiltrating immune cells ([@b59-ce-1-013]). Angiotensin II has also been shown to be involved in tissue repair and remodeling.

The initial development of peptides as renin inhibitors began around the same time as the development of ARBs, but problems with oral bioavailability and cost prevented the clinical development of these earlier versions ([@b31-ce-1-013]; [@b50-ce-1-013]; [@b24-ce-1-013]). These challenges were overcome in the development of aliskiren through the use of molecular modeling to design a small molecule drug with high affinity and specificity for renin, better oral bioavailability, and a long *in vivo* activity that had the potential for once-daily dosing ([@b69-ce-1-013]).

The attributes of renin inhibitors theoretically meet some of the unmet needs in the treatment of patients with hypertension. By inhibiting the first and rate-limiting step in the RAS system (conversion of angiotensinogen to angiotensin I), aliskiren may block the generation of angiotensin II more completely than ACE inhibitors because there is no other substantive pathway for angiotensin I production ([@b55-ce-1-013]). In contrast, angiotensin II, the major effector regulating blood pressure, can be synthesized by alternative pathways ([@b68-ce-1-013]). Thus, a more complete block of angiotensin II production via renin inhibition could provide an advantage, perhaps increasing the effectiveness of monotherapy.

Aliskiren is currently in phase III trials for use as monotherapy and in phase II trials in combination with valsartan, in patients with uncomplicated mild-to-moderate hypertension. It is also being studied in phase II trials in patients with hypertension and diabetic nephropathy. Regulatory submission is expected to be filed in early 2006.

Disease overview
================

Hypertension is a common disease that affects approximately 50 million people in the USA and about 1 billion people worldwide ([@b44-ce-1-013]). The most common sequela of hypertension, cardiovascular disease, is also the most frequent cause of death in industrialized countries. The World Health Organization (WHO) estimates that there are 7.1 million deaths (13% of total deaths) annually due to complications of hypertension ([@b63-ce-1-013]). The worldwide prevalence of hypertension is increasing; recent studies estimate that the prevalence will increase by 60%, from 26.4% in 2000 to 29.2% by 2025 ([@b36-ce-1-013]).

Although hypertension is a worldwide problem, sample surveys from the 1990s have shown that its prevalence differs between regions of the world. For example, in North America the prevalence of hypertension is about 28% compared with about 44% in Europe ([@b66-ce-1-013]). A recent analysis of surveys found that the highest estimated prevalence for men was in Latin America and the Caribbean (Mexico, Paraguay, and Venezuela) and for women in former socialist economies (e.g. Slovakia); for both sexes the lowest prevalence was in Asian regions (e.g. Korea, Thailand, Taiwan) ([@b36-ce-1-013]).

In addition to geographic differences, the prevalence of hypertension also differs by race. For example, in the USA about 28% of Caucasians are hypertensive compared with 40--43% of African-Americans ([@b43-ce-1-013]). A recent study has shown, however, that there are wide variations in hypertension prevalence in both black (14--44%) and white (27--55%) populations worldwide, and highlighted the importance of not overlooking environmental factors that impact hypertension prevalence rates ([@b16-ce-1-013]).

Some regional differences can be explained by genetic factors and population demographics. In addition to race, family history of hypertension confers significant additional risk, since the genetic heritability of hypertension is about 30% ([@b1-ce-1-013]). Age is another significant risk factor for developing hypertension. Data from the Framingham Heart Study show that the residual lifetime risk for developing hypertension in a normotensive, 55-year-old person is 90% ([@b61-ce-1-013]). Obesity is also a significant risk factor.

Awareness, treatment, and control of hypertension remain significant challenges. Most people with hypertension are undiagnosed, untreated, or undertreated, despite educational campaigns and the availability of many generally well-tolerated antihypertensive drugs. In the USA, data from the National Health and Nutrition Examination Survey (NHNES) found that 30% of people with hypertension were unaware of their condition, 41% were not treated, and 66% of those with hypertension were not well controlled ([@b44-ce-1-013]). Another study among patients with hypertension found that 71% in the USA, 83% in Canada, and more than 90% in Europe were not well controlled ([@b67-ce-1-013]).

However, for those patients who are appropriately treated, effective blood pressure lowering has been shown to decrease the incidence of stroke by between 30 and 39%, coronary heart disease by 20%, and major cardiovascular events by 21--28% ([@b46-ce-1-013]). In patients with stage 1 hypertension (systolic blood pressure 140--159 mmHg and/or diastolic blood pressure 90--99 mmHg), it has been estimated that a 12 mmHg reduction of blood pressure for 10 years prevents one death for every 11 moderate-risk patients treated, while a similar blood pressure reduction in higher risk patients with cardiovascular disease and target organ damage prevents one death for every nine patients treated ([@b44-ce-1-013]).

The sequelae of hypertension can have a significant impact on patient quality of life in those who are not well controlled. Interestingly, although there is the perception of a substantial adverse impact on quality of life arising from pharmacologic treatment, this has not been borne out in the literature ([@b8-ce-1-013]; [@b9-ce-1-013]; [@b25-ce-1-013]; [@b20-ce-1-013]).

Given the prevalence of hypertension, it follows that its economic and societal burdens are enormous. In economic terms, it is estimated that the USA spends more than \$US59.7 billion annually on the direct and indirect costs of treating hypertension ([@b2-ce-1-013]). Expenditures related to hypertension as well as cardiovascular complications and other diagnoses related to hypertension were estimated to be \$US108 billion in 1998 in the USA ([@b29-ce-1-013]). In addition, the complexity of antihypertensive care, such as patient visits to ensure treatment adherence and the care issues associated with the adverse outcomes associated with uncontrolled hypertension, in an increasingly elderly Western population represents a significant societal burden.

Current therapy options
=======================

Evidence-based treatment guidelines for hypertension emphasize the importance of lifestyle modifications, including weight loss in the overweight or obese, reduction in dietary sodium intake, applying the DASH (Dietary Approaches to Stop Hypertension) diet, increasing physical activity, and limiting alcohol intake, as the first step in treatment ([@b62-ce-1-013]; [@b44-ce-1-013]; [@b64-ce-1-013]). Lifestyle modification is indicated for all hypertensive patients; however, it rarely reduces blood pressure sufficiently and recent data underscore the importance of rapid blood pressure control ([@b34-ce-1-013]). Therefore pharmacotherapy is generally started in most patients.

Current pharmacologic options for the treatment of hypertension include diuretics, beta blockers, ACE inhibitors, ARBs, aldosterone receptor blockers, calcium channel blockers, and alpha-1 blockers, together with various combinations of these drugs ([@b4-ce-1-013]). Although there is debate over which drug to use as initial therapy, it is generally accepted that the majority of patients will not be well controlled on one drug and will require multidrug therapy. In addition, outcome studies have shown that, in general, regardless of drug choice, larger decreases in blood pressure lead to larger reductions in cardiovascular risks ([@b54-ce-1-013]; [@b60-ce-1-013]).

The relatively recent conclusion of major clinical trials and the publication of new systematic reviews have shed light but also created debate regarding the comparative efficacy of various antihypertensive therapies as measured by clinically relevant outcomes ([@b3-ce-1-013]; [@b17-ce-1-013]; [@b40-ce-1-013]; [@b40-ce-1-013]; [@b65-ce-1-013]; [@b18-ce-1-013]; [@b34-ce-1-013]). The results from some of these clinical trials together with systematic reviews ([@b42-ce-1-013]; [@b46-ce-1-013]; [@b54-ce-1-013]; [@b48-ce-1-013]; [@b60-ce-1-013]) have prompted the release of new treatment guidelines from many countries and organizations. These include updated guidelines from the USA ([@b44-ce-1-013]), Canada ([@b15-ce-1-013]), the WHO/International Society of Hypertension (ISH) ([@b62-ce-1-013]), the European Society of Hypertension/European Society of Cardiology ([@b22-ce-1-013]), the British Hypertension Society ([@b64-ce-1-013]), and [@b45-ce-1-013] ([Table 2](#t2-ce-1-013){ref-type="table"}). The USA, Canadian, European, and WHO guidelines have lower overall thresholds for treatment of hypertension (≥140/90 mmHg except patients in special categories) compared with a threshold of ≥160/100 mmHg in the British and NICE guidelines. In addition, the British and NICE guidelines recommend a higher threshold (≥140/90 mmHg) for treatment of patients with additional morbidities, compared with a lower threshold (≥130/80 mmHg) in the other guidelines. Finally, several of the guidelines encourage an overall assessment of cardiovascular risk, rather than isolated treatment of hypertension, something also emphasized in a recent review ([@b32-ce-1-013]).

It is notable that the USA guidelines have established a category of "pre-hypertension," defined as 120--139/80--89 mmHg, recommending intervention with lifestyle modification, but not pharmacotherapy; individuals 65 years and older in this category are twice as likely to develop hypertension than those with lower blood pressure ([@b44-ce-1-013]). The USA, NICE, and WHO/ISH guidelines also include a highly debated endorsement of low-dose thiazide diuretics for initial therapy (see [Table 2](#t2-ce-1-013){ref-type="table"}).

All the guidelines emphasize the fact that many patients need combination therapy for blood pressure control. To that end, a randomized clinical trial directly comparing two different combinations of drugs, benazapril/hydrochlorothiazide and amlodipine/benazapril, began enrolling patients in 2003 with the trial expected to conclude in 2008 ([@b33-ce-1-013]). In addition, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which is comparing the efficacy of a calcium channel blocker alone or in combination with an ACE inhibitor, with a beta blocker with or without a diuretic in high-risk patients ([@b52-ce-1-013]), was stopped early because of significant reductions in moratlity with the calcium channel blocker/ACE inhibitor combination ([@b5-ce-1-013]).

Unmet needs
===========

Despite the availability of many effective, well-tolerated drugs, a significant proportion of treated hypertensive patients remain uncontrolled and face serious morbidity and mortality as a consequence.

Adherence
---------

Adherence to treatment regimens for hypertension remains a major challenge and has been shown to be as low as 30% in some studies ([@b19-ce-1-013]). Contributing factors for nonadherence may include patient age, drug tolerability, the largely asymptomatic nature of the disease, lack of patient education regarding adverse outcomes, and the complexities of combination drug regimens.

Various studies of interventions aimed at improving adherence, such as pharmacist and pharmacist/physician intervention, have shown some positive effects on adherence and reduction in blood pressure, including a lower visit cost per patient ([@b10-ce-1-013]; [@b14-ce-1-013]). A review of adherence interventions found that simplification of drug dosing regimens increased adherence between 8 and 19.6% (seven of nine studies); motivational strategies increased adherence up to 23% (10 of 24 studies); and interventions using multiple techniques increased adherence from 5 to 41% (eight of 18 studies) ([@b51-ce-1-013]). The review concluded that reducing the number of daily doses of medication seemed to be effective, and, while the motivational and more complex interventions appeared somewhat effective, there was a need for more carefully designed studies to gauge the true impact of such strategies.

Tolerability
------------

In addition to education and the complexities of antihypertensive treatment regimens, treatment-related adverse effects may contribute to poor adherence rates ([@b13-ce-1-013]). While some antihypertensive medications are very well tolerated, particularly the ARBs, like all drugs antihypertensive therapies have adverse effects that limit their utility in some patients ([@b4-ce-1-013]), particularly in specific patient populations. Therefore improvement in tolerability remains a goal of future drug development.

Multidrug therapy
-----------------

A further unmet challenge in the pharmacotherapy of hypertension is the reality that most patients need treatment with more than one antihypertensive drug, which may lead to additional adverse events and a further decrease in adherence. This is particularly true in patients with chronic kidney disease who often need more than two drugs to control their hypertension. Therefore a drug that can be used in monotherapy remains a goal of future drug development, although it is questionable whether it can be realistically achieved.

Given these unmet needs, although clinical outcome trials ideally need to measure long-term mortality, they should first focus on the extent of blood pressure reduction (which correlates well with long-term outcomes), tolerability, and adherence to therapy.

Recent clinical trials and systematic reviews of trials have emphasized that the magnitude of blood pressure reduction is the most important contributor to decreasing morbidity and mortality in patients with hypertension. Blood pressure is therefore an acceptable surrogate outcome in preliminary short-term trials.

Outcomes achieved with aliskiren in clinical development
========================================================

Phase II trials of aliskiren in patients with uncomplicated mild-to-moderate hypertension are complete. The outcomes studied include blood pressure reduction with use in monotherapy or in combination with ARBs (pilot study only), and tolerability.

Blood pressure reduction with monotherapy
-----------------------------------------

Aliskiren entered phase II trials for treatment of mild-to-moderate hypertension following pilot studies that demonstrated treatment-related reduction in angiotensin II levels ([@b30-ce-1-013]; [@b47-ce-1-013]). There is now good phase II evidence that aliskiren reduces blood pressure significantly compared with placebo and that it is as effective as losartan and irbesartan ([Table 3](#t3-ce-1-013){ref-type="table"}). Aliskiren 150 or 300 mg once daily were as effective as an ARB (losartan 100 mg or irbesartan 150 mg) and significantly more effective than placebo in reducing systolic and diastolic blood pressure ([@b55-ce-1-013]; [@b28-ce-1-013]).

This evidence from phase II trials is being verified in phase III trials, including a trial outlined in [Table 4](#t4-ce-1-013){ref-type="table"}, which should provide more level 2 evidence of the effectiveness of aliskiren as monotherapy on blood pressure reduction in patients with mild-to-moderate hypertension. Early results from these trials are not yet publicly available.

Combination therapy with ARBs
-----------------------------

As most patients will require combination therapy it will be important to evaluate the use of aliskiren in combination with other antihypertensives. A small double-blind, placebo-controlled, pilot study in 12 healthy, mildly sodium-depleted normotensive volunteers examined the blood pressure lowering effects of single doses of aliskiren 300 mg, valsartan 160 mg, a lower-dose combination of the two drugs (aliskiren 150 mg and valsartan 80 mg), and placebo over a 48-h period ([@b6-ce-1-013]) (see [Table 3](#t3-ce-1-013){ref-type="table"}). Four hours after treatment the lower-dose combination treatment was as effective as the higher doses of each individual drug and significantly lowered mean arterial pressure compared with placebo. It should be emphasized that this was a pilot study performed in normotensive volunteers.

To expand upon these preliminary results and to attempt to provide evidence for use of aliskiren in combination therapy, a phase II trial in patients with hypertension is examining the effects of treatment with aliskiren and valsartan on blood pressure reduction (see [Table 4](#t4-ce-1-013){ref-type="table"}).

Tolerability
------------

The adverse effect profiles of current antihypertensive drugs can, in part, be attributed to their sites of action or influence on downstream mediators. For example, ACE affects the metabolism of bradykinin and increases circulating and tissue concentrations of substance P which, while contributing to the blood pressure lowering effect of ACE inhibitors, may also cause troublesome adverse effects including cough and angioedema that limit their clinical use ([@b58-ce-1-013]). Furthermore, blocking the RAS with ARBs inhibits activation at the AT-1 subtype of angiotensin II receptors, but since angiotensin II production is not blocked with these drugs, it can still act at other sites. Aliskiren was developed for its specificity and high affinity for renin thereby minimizing its potential to act at alternative sites and theoretically minimizing potential adverse effects. There are, however, local renin systems where renin inhibition would not be desirable. For example, the potential role of renin in the uterus may limit aliskiren's use to nonpregnant women ([@b53-ce-1-013]).

Evidence to date shows that aliskiren has a favorable adverse-effect profile. Adverse effects associated with aliskiren were similar in severity and incidence to those reported in patients treated with losartan or irbesartan. The most commonly reported adverse effects were fatigue or weakness, gastrointestinal disorders, dizziness, and headache ([@b55-ce-1-013]; [@b28-ce-1-013]). Of those patients in whom a serious adverse event occurred or who experienced an adverse event leading to withdrawal from the study, one of two in the 37.5 mg aliskiren treatment arm, three of three in the 75 mg aliskiren arm, two of three in the 300 mg aliskiren arm, and one of three in the 100 mg losartan treatment arm had events that may have been related to drug treatment; no patients in the 150 mg aliskiren arm had serious adverse events ([@b55-ce-1-013]). In another study, no serious adverse events were reported in patients treated with aliskiren although one patient in the 600 mg treatment arm stopped treatment because of elevated serum glutamic-oxaloacetate transaminase (SGOT) and bilirubin and increased diastolic blood pressure ([@b28-ce-1-013]). Furthermore, there is evidence that aliskiren does not interact with warfarin ([@b21-ce-1-013]), a commonly co-prescribed drug particularly in elderly patients with stroke risk, thus widening the proportion of patients for whom aliskiren may be an option.

Adherence
---------

Adherence to antihypertensive therapy is a complex issue influenced by many variables. One important factor is drug tolerability; drugs associated with fewer adverse events have higher adherence and persistence rates ([@b26-ce-1-013]; [@b39-ce-1-013]).

There is preliminary evidence from one study that adherence to aliskiren therapy is high, averaging \>95% in patients treated with aliskiren (37.5, 75, 150, or 300 mg once daily) or losartan (100 mg once daily) for 4 weeks ([@b55-ce-1-013]). These adherence measures are not sufficient, however, and more studies are needed.

Resource utilization
====================

The economic burden of treating hypertension is estimated to be almost \$US60 billion per year in the USA ([@b2-ce-1-013]). It is estimated that the direct costs of drug therapy alone account for a large proportion (about 50%) of the direct health costs of treating hypertension ([@b2-ce-1-013]) and therefore cost-effectiveness ratios are highly dependent on the choice of drug.

However, drug acquisition cost is just one component for consideration when evaluating the economic impact of treating patients with hypertension. For example, studies have shown that it is more cost-effective to treat more severe hypertension compared with less severe disease, to treat older versus younger patients, and to treat men versus women ([@b35-ce-1-013]; [@b57-ce-1-013]).

There is no economic evidence for the use of aliskiren in the treatment of hypertension. Economic studies show thiazide diuretics are currently the most cost-effective agents because of their low acquisition cost ([@b49-ce-1-013]; [@b23-ce-1-013]) and aliskiren, due to the complexity of the manufacturing process, is likely to have high acquisition costs. Nevertheless, there is clearly a role for other commonly used drug classes, including ACE inhibitors, ARBs, and calcium channel blockers in the management of patients with hypertension based on better clinical outcomes and patient preferences, e.g. tolerability. Cost-benefit and cost-effectiveness comparisons of aliskiren with these drug classes and in specific patient groups would therefore be welcome. Furthermore, evidence related to any total cost-benefit of treatment with aliskiren that included indirect costs, benefits in terms of primary outcome prevention, and tolerability would provide a more comprehensive view of its potential clinical utility.

Patient group/population
========================

To date, aliskiren has been studied in completed phase II trials and ongoing phase III trials in patients with uncomplicated mild-to-moderate hypertension. The existing evidence suggests that aliskiren effectively lowers blood pressure and is associated with good tolerability in this patient population.

However, hypertension is associated with many other comorbid conditions and aliskiren is currently in phase II trials for treatment of some of these populations, including diabetic nephropathy. Treatment of hypertensive patients with and without diabetes with ACE inhibitors or ARBs, inhibitors of the RAS, has been shown to reduce progression to macroalbuminuria, reduce albuminuria, and slow the progression of diabetic nephropathy independent of their effects on arterial blood pressure ([@b37-ce-1-013]; [@b27-ce-1-013]; [@b12-ce-1-013]; [@b38-ce-1-013]; [@b70-ce-1-013]).

Intraglomerular hypertension is thought to be a causative factor in the progression of diabetic nephropathy as well as other chronic nephropathies. Angiotensin II leads to constriction of afferent and efferent glomerular arterioles; these effects are more prominent in the efferent arteriole and the net result is an increase in glomerular perfusion pressure. Both ACE inhibitors and ARBs, by inhibiting angiotensin II production/action, decrease glomerular pressure ([@b11-ce-1-013]). Renin inhibitors including aliskiren inhibit angiotensin II more completely than ARBs and ACE inhibitors and therefore would be expected to more effectively limit glomerular hypertension.

Indeed, it had been previously demonstrated, in earlier attempts at renin inhibitor drug development, that these drugs cause renal vasodilatory responses that are 50% greater than those seen with ACE inhibitors ([@b31-ce-1-013]). Aliskiren could therefore be more effective than existing therapies in treatment of diabetic nephropathy in patients with or without hypertension, and treatment of chronic kidney disease in patients with or without diabetes, but to date there is no clinical evidence of its efficacy in these patient populations. Furthermore, it is unclear whether more complete angiotensin II blockade will lead to clinically relevant incremental benefits. In addition glomerular filtration rate (GFR) is a function of perfusion pressure and more complete blockade of angiotensin II could lead to excessive decreases in GFR thereby limiting the drug's utility in patients with chronic kidney disease. This is an important topic that warrants further studies.

The effectiveness of aliskiren in other high-risk patient populations, such as those with severe hypertension or other cardiovascular risk factors (chronic heart failure, previous myocardial infarction, stroke, etc.) is unknown. Its effectiveness in other races (particularly African-Americans), or special populations, such as the elderly and children, also remains to be determined.

Clinical potential
==================

The existing clinical and economic burden of hypertension underscores the significant needs that remain regarding hypertension therapy. In an attempt to address some of these needs, aliskiren was developed using rational drug design principles. These principles indicate that theoretically aliskiren should be as effective as current treatments, but with tolerability and adherence advantages.

There is strong preliminary evidence that aliskiren as monotherapy given once daily is effective at reducing blood pressure in patients with mild-to-moderate hypertension. In addition, there is some evidence that aliskiren is comparable in efficacy to the ARBs losartan and irbesartan. Clinical trials to date have also shown that aliskiren is well tolerated, with adverse effect and adherence rates comparable to ARBs. A good tolerability profile together with once-daily administration may be expected to positively influence adherence and quality of life, both of which can be significant barriers to effective disease management in patients with hypertension. Phase III trials are currently underway, which may attempt to confirm these phase II data.

For patients whose blood pressure can be controlled with single-agent therapy, aliskiren may offer another well-tolerated, effective alternative, but most patients with hypertension eventually need a second antihypertensive drug. There is some evidence that aliskiren combined with an ARB is effective in reducing blood pressure. To date, one small, short-term (48 h) published pilot study has shown that aliskiren effectively lowers blood pressure when used in combination with the ARB valsartan in normotensive individuals. Phase II trials in patients with mild-to-moderate hypertension are currently underway (see [Table 4](#t4-ce-1-013){ref-type="table"}).

In addition, if current phase II trials and future phase III trials in patients with diabetic nephropathy provide clinical evidence of its effectiveness, then aliskiren might prove to be of significant benefit in these patients. Further evidence will therefore be needed to demonstrate aliskiren's effectiveness in this and other patient groups, such as those with severe hypertension, the elderly, and those with other risk factors, e.g. chronic heart failure and chronic kidney disease.

There is strong phase II evidence that aliskiren effectively lowers blood pressure and blood pressure reduction is a valid predictor of reduced mortality and cardiovascular events. On this basis, although there are currently no long-term outcome data with aliskiren on its effects on mortality and/or major cardiovascular events, the evidence regarding its effect on blood pressure lowering suggests that it is likely to be effective in reducing mortality.

Evidence suggests that treatment with the other RAS inhibitors, ACE inhibitors, or ARBs, can have positive cardiovascular effects that are independent of blood pressure control. Therefore aliskiren has the potential to have similar effects, acting as it does on the first step in the RAS pathway, effectively blocking the production of angiotensin II.

The precise economic impact of aliskiren is still unclear. However, if its good tolerability profile and effectiveness are confirmed in phase III studies, aliskiren may be a cost-effective option in the treatment of hypertension, especially in patient populations where it may prove to have a therapeutic advantage, e.g. patients with diabetic nephropathy.

In summary, the available outcomes evidence for aliskiren from phase II trials is encouraging and shows that it is effective in patients with mild-to-moderate hypertension in monotherapy and possibly as effective an ARB. Moreover, if the evidence from phase II and III trials of aliskiren in combination therapy demonstrates an antihypertensive effect of similar magnitude to existing combination drugs, this in addition to its good tolerability profile and once-daily dosing will support its use.

![The renin-angiotensin system and pharmacotherapy](ce-1-013f1){#f1-ce-1-013}

###### 

Evidence base included in the review

  **Category**                    **Number of records**   
  ------------------------------- ----------------------- -------------------------------------------
  Initial search                  26                      1
    records excluded              22                      0
    records included              4                       1[a](#tfn2-ce-1-013){ref-type="table-fn"}
  Additional studies identified   1                       0
  Level 1 clinical evidence       0                       0
  Level 2 clinical evidence       5                       0
  Level ≥3 clinical evidence      0                       0
    trials other than RCT         0                       0
    case reports                  0                       0
  Economic evidence               0                       0

Included in the original review and later excluded because the same study was identified later as a full paper.

RCT, randomized controlled trial

###### 

Comparison of current hypertension guidelines

  **Guideline**                                                                                             **Prehypertension**   **Initial therapy[a](#tfn4-ce-1-013){ref-type="table-fn"}**   **Threshold for pharmacologic intervention (mmHg) SBP/DBP**   
  --------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------
  USA[c](#tfn6-ce-1-013){ref-type="table-fn"}                                                               Yes                   Low-dose thiazide diuretic                                    ≥140/90                                                       \>130/80
  WHO/ISH[d](#tfn7-ce-1-013){ref-type="table-fn"}                                                           No                    Low-dose thiazide diuretic                                    ≥140/90                                                       ≥130/80
  European Society of Hypertension/European Society of Cardiology[e](#tfn8-ce-1-013){ref-type="table-fn"}   No                    Not specified                                                 ≥140/90                                                       ≥130--139/85--89
  British Hypertension Society[f](#tfn9-ce-1-013){ref-type="table-fn"}                                      No                    Not specified                                                 ≥160/100                                                      ≥140--159/90--99
  Canadian[g](#tfn10-ce-1-013){ref-type="table-fn"}                                                         No                    Not specified                                                 ≥140/90                                                       ≥130/80
  NICE[h](#tfn11-ce-1-013){ref-type="table-fn"}                                                             No                    Low-dose thiazide diuretic                                    ≥160/100                                                      ≥140/90

For most patients with uncomplicated hypertension.

For patients with additional morbidities (see individual guidelines for details).

[@b44-ce-1-013].

[@b62-ce-1-013].

[@b22-ce-1-013].

[@b64-ce-1-013].

[@b15-ce-1-013].

[@b45-ce-1-013].

SBP/DBP, systolic/diastolic blood pressure.

###### 

Aliskiren as monotherapy and in combination therapy: effects on blood pressure

  **Level of evidence**             **Once-daily drug dose (mg) (n)**   **Duration**        **Results ± standard deviation**                              **Reference**     **Comment**
  --------------------------------- ----------------------------------- ------------------- ------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------
                                                                                            **Mean ↓daytime ambulatory SBP mmHg**                                           
  2                                 Aliskiren 37.5 (45)                 4 weeks             0.4±11.7                                                      [@b55-ce-1-013]   No placebo arm; ANCOVA treatment effect, *P*=0.0002
  Aliskiren 75 (46)                                                     5.3±11.3                                                                                            
  Aliskiren 150 (44)                                                    8±11                                                                                                
  Aliskiren 300 (47)                                                    11±11                                                                                               
  Losartan 100 (44)                                                     10.9±13.8                                                                                           
                                                                                            **Least-squares mean↓SBP/DBP mmHg**                                             
  2                                 Aliskiren 150 (127)                 8 weeks             11.4±1.3/9.3±0.8                                              [@b28-ce-1-013]   Low dose of irbesartan used; usual dose 150--300 mg; *P*\<0.001 for all doses vs placebo
  Aliskiren 300 (130)                                                   15.8±1.2/11.8±0.8                                                                                   
  Aliskiren 600 (130)                                                   15.7±1.2/11.5±0.8                                                                                   
  Irbesartan 150 (134)                                                  12.5±1.2/8.9±0.7                                                                                    
  Placebo (131)                                                         5.3±1.2/6.3±0.8                                                                                     
                                                                                            **Absolute change in mean arterial pressure 4 h post-dose**                     
  2                                 Aliskiren 300 (12)                  48 h                4.9±5.6                                                       [@b6-ce-1-013]    Study population was mildly sodium-depleted normotensive healthy volunteers; *P*\<0.01 for all treatments vs placebo 4 h post-dose
  Valsartan 160 (12)                                                    6.6±5                                                                                               
  Aliskiren 150/Valsartan 80 (12)                                       7.4±5.2                                                                                             
  Placebo (12)                                                          0.3±5.6                                                                                             

###### 

Ongoing phase II and III randomized placebo-controlled trials with aliskiren (results from these trials are not yet publicly available)

  **Regimen**                                                                   **Drug dosage**   **n (total)**   **Endpoint**                             **Duration**   **Inclusion**                                                            **Exclusion**                                              **Phase**
  ----------------------------------------------------------------------------- ----------------- --------------- ---------------------------------------- -------------- ------------------------------------------------------------------------ ---------------------------------------------------------- -----------
  Monotherapy[a](#tfn13-ce-1-013){ref-type="table-fn"}                          Not stated        1064            Blood pressure lowering                  Not stated     Mild-to-moderate hypertension                                            Not stated                                                 III
  Combination therapy with valsartan[b](#tfn14-ce-1-013){ref-type="table-fn"}   Not stated        Not stated      Blood pressure lowering                  Not stated     Mild-to-moderate hypertension                                            Not stated                                                 II
  Monotherapy[c](#tfn15-ce-1-013){ref-type="table-fn"}                          Not stated        496             Reduction in level of protein in urine   Not stated     Hypertension; elevated serum protein levels; confirmed type 2 diabetes   Certain diseases; uncontrolled diabetes; type 1 diabetes   II

Manufacturer press release, January 21, 2005.

Manufacturer press release, January 21, 2005.

Clinical Trials Database [www.clinicaltrials.gov](www.clinicaltrials.gov), accessed January 7, 2005.
